# Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

> **NCT05817214** · PHASE2 · RECRUITING · sponsor: **Zhongnan Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Anlotinib
- **DRUG:** Granulocyte-Macrophage Colony-Stimulating Factor

## Key facts

- **NCT ID:** NCT05817214
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-16
- **Primary completion:** 2025-11-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817214, "Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05817214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*